These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31648851)

  • 21. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.
    Tan EH; Szczesna A; Krzakowski M; Macha HN; Gatzemeier U; Mattson K; Wernli M; Reiterer P; Hui R; Pawel JV; Bertetto O; Pouget JC; Burillon JP; Parlier Y; Abratt R;
    Lung Cancer; 2005 Aug; 49(2):233-40. PubMed ID: 16022917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.
    Rodriguez-Vida A; Valderrama BP; Castellano D; Pinto A; Mellado B; Puente J; Climent MA; Domenech M; Vazquez F; Perez-Gracia JL; Bonfill T; Morales-Barrera R; Gonzalez-Billalabeitia E; Garcia-Del-Muro X; Maroto P; Navarro-Gorro N; Juanpere N; Juan O; Bellmunt J
    ESMO Open; 2024 Sep; 9(9):103690. PubMed ID: 39214051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
    Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
    J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
    Krege S; Rexer H; vom Dorp F; de Geeter P; Klotz T; Retz M; Heidenreich A; Kühn M; Kamradt J; Feyerabend S; Wülfing C; Zastrow S; Albers P; Hakenberg O; Roigas J; Fenner M; Heinzer H; Schrader M
    BJU Int; 2014 Mar; 113(3):429-36. PubMed ID: 24053564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial.
    Grigorescu AC; Draghici IN; Nitipir C; Gutulescu N; Corlan E
    Lung Cancer; 2002 Jul; 37(1):9-14. PubMed ID: 12057861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
    Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
    J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer].
    Sumiyoshi T; Matsumoto K; Utsunomiya N; Segawa T; Muguruma K; Kawakita M
    Hinyokika Kiyo; 2013 Jan; 59(1):1-6. PubMed ID: 23412116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
    Geldart T; Chester J; Casbard A; Crabb S; Elliott T; Protheroe A; Huddart RA; Mead G; Barber J; Jones RJ; Smith J; Cowles R; Evans J; Griffiths G
    Eur Urol; 2015 Apr; 67(4):599-602. PubMed ID: 25465968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine Plus Cisplatin Split
    Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
    In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
    Lehmann J; Retz M; Steiner G; Albers P; Jaeger E; Knuth A; Lippert C; Koser M; Stockamp K; Otto C; Melchior H; Fassmann C; Potratz C; Loch T; Derigs HG; Becker T; Kälble T; Piechota HJ; Hertle L; Weinknecht S; Weissbach L; Al-Mwalad M; Hamza A; Henss H; Brkovic D; Pomer S; Roloff J; Walz P; Muschter R; Tunn U; Winter E; Bub P; Kaldenbach U; Roth S; Brauers A; Jakse G; Richter AE; Wirth M; Hartlapp J; Van Ahlen H; Stöckle M
    Urologe A; 2003 Aug; 42(8):1074-86. PubMed ID: 14513232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
    Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
    Pectasides D; Aravantinos G; Kalofonos H; Kiamouris C; Bafaloukos D; Xiros N; Nicolaides C; Visvikis A; Dimopoulos MA
    Ann Oncol; 2001 Oct; 12(10):1417-22. PubMed ID: 11762814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
    Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N
    Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma.
    Mitsuzuka K; Yamashita S; Namiki S; Yamada S; Sato K; Saito H; Kaiho Y; Ito A; Nakagawa H; Arai Y
    Int J Urol; 2014 Nov; 21(11):1114-9. PubMed ID: 24962105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.
    Bamias A; Moulopoulos LA; Koutras A; Aravantinos G; Fountzilas G; Pectasides D; Kastritis E; Gika D; Skarlos D; Linardou H; Kalofonos HP; Dimopoulos MA
    Cancer; 2006 Jan; 106(2):297-303. PubMed ID: 16342065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].
    Ito H; Aoki Y; Oyama N; Miwa Y; Akino H; Yokoyama O
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):481-4. PubMed ID: 21403460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
    Galsky MD; Iasonos A; Mironov S; Scattergood J; Boyle MG; Bajorin DF
    Cancer; 2007 Feb; 109(3):549-55. PubMed ID: 17200962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma.
    Kim YR; Lee JL; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):141-53. PubMed ID: 26001531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.